Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06150183 · ClinicalTrials.gov registry record · Phase 1
Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors
A Phase 1 study of Advanced Malignant Solid Tumor, sponsored by BioNTech SE.
- Active
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 14
- Study locations
NCT06150183: Active Phase 1 study of Advanced Malignant Solid Tumor, sponsored by BioNTech SE.
NCT06150183 is a Phase 1 study of Advanced Malignant Solid Tumor that is active but no longer recruiting, run by BioNTech SE. The registered enrollment target is 41 participants, below the 70-participant average among 3 other Advanced Malignant Solid Tumor trials with a reported enrollment target (41% lower). The trial reports 14 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06150183, a Phase 1 study of Advanced Malignant Solid Tumor, is active but no longer recruiting, sponsored by BioNTech SE.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this first-in-human study is to find out if BNT314 is safe when it is used alone in patients with different types of cancer. This is a dose escalation study in which patients will be assigned to multiple dose levels (DLs) of BNT314 given alone. By escalating the dose with a small group of patients, the Maximum Tolerated Dose which is the highest dose with acceptable safety and manageable side effects, or the maximum administered dose will be investigated.
Conditions Studied
Interventions
- BIOLOGICAL BNT314
Study Locations (14)
Other
- GZA Ziekenhuizen - Antwerp
- CHU de Liège - Liège
- Rigshospitalet - Copenhagen
- National Cancer Center Hospital East - Kashiwanoha
- Hospital Quironsalud Barcelona (NEXT Barcelona) - Barcelona
- Hospital Fund. Jiménez Dia - Madrid
- Hospital HM Univ. Sanchinarro, Ensayos START - Madrid
- Clinica Universidad de Navarra - Pamplona
- Royal Marsden Hospital - London - London
- The Christie Hospital - Manchester
- Northern Centre for Cancer Care - Newcastle
Michigan
- START Midwest - Grand Rapids
North Carolina
- Carolina BioOncology Institute, LLC - Huntersville
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2023-11-30 |
| Est. Completion | 2028-03 |
| Phase | Phase 1 |
What the registry record for NCT06150183 still lists
NCT06150183 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 70-participant average among 3 other Advanced Malignant Solid Tumor trials with a reported enrollment target (41% lower).
The record links to 1 condition, with Advanced Malignant Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which BNT314 is the first listed.
NCT06150183 lists 14 locations in 4 states (Other, Michigan, North Carolina).
Frequently Asked Questions
What is clinical trial NCT06150183 about?
NCT06150183 is a clinical study titled "Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors". The purpose of this first-in-human study is to find out if BNT314 is safe when it is used alone in patients with different types of cancer. This is a dose escalation study in which patients will be assigned to multiple dose levels (DLs) of BNT314 given alone. By escalating the dose with a small gro...
What is the current status of trial NCT06150183?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2023-11-30. Estimated completion is 2028-03.
What conditions does trial NCT06150183 study?
This clinical trial studies the following conditions: Advanced Malignant Solid Tumor.
What interventions are being tested in trial NCT06150183?
The interventions under investigation include: BNT314 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06150183?
This trial is sponsored by BioNTech SE, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06150183 being conducted?
This trial has 14 study locations across Michigan, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Malignant Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
RECRUITING · Phase 1
-
An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI